Find updates on the work of our researchers here, as well as news about recent advances in Alzheimer's science, funding and awareness.

Rotary and Cure Alzheimer's Fund Co-Sponsor Research Focusing on Why Women Get Alzheimer's More Than Men

(CHICAGO, IL) – OCTOBER 7, 2016 – Rotary and Cure Alzheimer’s Fund today announced an agreement to co-fund a new, groundbreaking research project to search for female-specific genetic and other factors contributing to women’s risk for Alzheimer’s disease. In total, the two organizations will provide a grant of $375,000 for this critical research.

Protecting Synapses in Adults: An Early Intervention for Alzheimer’s?

What do the developing brain and the Alzheimer’s brain have in common? Beth Stevens, Ph.D., a developmental neurologist, is investigating an important connection: the loss of synapses, where neurons connect with one another to transmit important signals.

A Growing Research Consortium

We are very pleased to announce the addition of Drs. Ben Barres, Bart De Strooper and Nancy Ip to our team of renowned global researchers.

Alumni Reunite

Henry McCance and Jeff Morby, co-chairmen and co-founders of Cure Alzheimer’s Fund and Harvard Business School (HBS) alumni, had their respective 50th and 55th reunions in June.

Morby made a presentation to 100 attendees of his reunion about the pathology of Alzheimer’s disease and the major research initiatives that have been funded by Cure Alzheimer’s Fund.

Cure Alzheimer's Fund Tops $6 Million in Research Spending

Nonprofit has funded 29 projects this year to help cure Alzheimer's disease, with more grants to come

WELLESLEY, Mass., Sept. 19, 2016 -- Cure Alzheimer's Fund has announced today that the nonprofit has issued more than $6 million in research grants this year to scientists looking to advance our knowledge of Alzheimer's disease or to develop effective therapies to treat or cure it. Since the beginning of the year, the organization has funded 29 projects across the country and around the world, with more grants to come.

CaringKind and Cure Alzheimer’s Fund create care and cure alliance

(New York City, NY) – August 8, 2016 – CaringKind, New York City’s leading expert in Alzheimer's and dementia care for the past three decades, has formed an alliance with Cure Alzheimer’s Fund, a non-profit dedicated to funding research to prevent, slow, or reverse the disease.

$10 Million in Funded Research in 2015

Thanks to the generosity of our growing donor base, in 2015 Cure Alzheimer’s Fund reached $10 million in research grants in a single year for the first time. Since our inception, we have provided $38 million to the field’s top scientists to accelerate their pursuit of a cure. We are thrilled with their progress and honored by our donors’ trust in us, but there is still much work to be done.  

Air Pollution and Alzheimer's: Sound the Alarm

New evidence—funded by Cure Alzheimer’s Fund (CAF) and others—has emerged suggesting a strong connection between air pollution and Alzheimer’s disease. “These findings underscore the complexity of this disease,” says CAF President and CEO Tim Armour, “and emphasize the need for a comprehensive approach to stop it.” 

Cure Alzheimer’s Fund Receives 100 Percent Rating from Charity Navigator

Organization achieves 4-star rating for 5th consecutive time

(Wellesley, MA) – June 2016 – Cure Alzheimer’s Fund is announcing that Charity Navigator has assigned the organization a score of 100 percent regarding its overall financial health. The nation's largest and most-utilized evaluator of charities, Charity Navigator assigned this score by evaluating two areas of the Fund’s performance – financial health and accountability/transparency – through the IRS Form 990.

Senate Appropriations Subcommittee Calls for 40% Increase in Funding for Alzheimer’s Research

Cure Alzheimer’s Fund is thankful to the Senate Appropriations Subcommittee for their support of increasing vital funding for Alzheimer’s disease research with the NIH. With a $400 million increase, the proposed budget for Alzheimer’s research at the NIH will reach close to $1.4 billion, nearly triple what it was three years ago, demonstrating the understanding in Congress of the need to continue to fund research to address the disease.